Clinical Trial Update: Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-daily versus three-times-daily dosing of mesalazine granules for prevention of Ulcerative Colitis recurrence has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mesalazine Granules (mesalazine)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Colitis, Ulcerative, Recurrence | Phase 3 | Status: COMPLETED